Haemonetics's Revenue in the fiscal year 2026 $ 1,333.59 millions
Haemonetics's Revenue in the fiscal year 2025 $ 1,359.96 millions
Haemonetics's Revenue in the fiscal year 2024 $ 1,308.55 millions
Haemonetics's Revenue in the fiscal year 2023 $ 1,168.10 millions
Haemonetics's Revenue in the fiscal year 2022 $ 992.50 millions
HAE Revenue first quarter 2027 Y/Y Growth Comment
Haemonetics Corporation reported Revenue growth of 5.65% year on year in the first quarter 2027, to $ 339.38 millions, this is lower than Haemonetics Corporation's recent average Revenue surge of 6.4952989703891E+16%.
Looking into first quarter 2027 results within Medical Equipment & Supplies industry 140 other companies have achieved higher Revenue growth. While Haemonetics Corporation' s Revenue increase of 5.65% ranks overall at the positon no. 2663 in the first quarter 2027.
Revenue by Quarter for the Fiscal Years 2024, 2025, 2026, 2027
Haemonetics's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
23.63 %
-1.97 %
-100 %
(Sep 29 2012)
HAE's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2027 Haemonetics Corporation disclosed fall in Revenue from the fourth quarter by -2.26% to $ 339.38 millions, from $ 347.21 millions achived in the previous reporting period.
But that's not important problem, as Haemonetics's Revenue generally seem to plunge in this quarter.
Within Medical Equipment & Supplies industry 83 other companies have achieved higher Revenue quarter on quarter growth. While Haemonetics's Revenue growth quarter on quarter, overall rank is 2138.
In the I. Quarter 2027 Haemonetics Corporation disclosed fall in Revenue from the fourth quarter by -2.26% to $ 339.38 millions, from $ 347.21 millions achived in the previous reporting period.
But that's not important problem, as Haemonetics's Revenue generally seem to plunge in this quarter.
Within Medical Equipment & Supplies industry 83 other companies have achieved higher Revenue quarter on quarter growth. While Haemonetics's Revenue growth quarter on quarter, overall rank is 2138.
Haemonetics's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Jun 27 2026)
12 Months Ending (Mar 28 2026)
12 Months Ending (Dec 27 2025)
12 Months Ending (Sep 27 2025)
12 Months Ending (Jun 28 2025)
Cumulative Revenue 12 Months Ending
$ 1,351.72
$ 1,333.59
$ 1,317.42
$ 1,326.59
$ 1,345.28
Y / Y Revenue Growth (TTM)
0.48 %
-1.94 %
-4.03 %
-2.54 %
0.91 %
Year on Year Revenue Growth Overall
Ranking
# 2162
# 1798
# 132
# 484
# 648
Seqeuential Revenue Change (TTM)
1.36 %
1.23 %
-0.69 %
-1.39 %
-1.08 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 2663
# 2224
# 234
# 893
# 1903
Cumulative Revenue growth Comment
Although Haemonetics's Annual Revenue growth year on year were below company's average 6.4952989703891E+16% , Revenue announced in the Jun 27 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 0.48% year on year, from -1.94% in Mar 28 2026.
In the Healthcare sector 322 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1798 to 2162.
Although Haemonetics's Annual Revenue growth year on year were below company's average 6.4952989703891E+16% , Revenue announced in the Jun 27 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 0.48% year on year, from -1.94% in Mar 28 2026.
In the Healthcare sector 322 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1798 to 2162.
About Haemonetics Revenue Growth Rates (HAE), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
9.79%